Latest From Biotech Now

What They’re Saying about the Medicare Part B Demo

health care, medicine

Back in March, CMS’s Center for Medicare and Medicaid Innovation (CMMI) proposed a sweeping demonstration project that would dramatically lower the rate at which many providers are reimbursed for medicines administered under Medicare Part B. Medicare Part B  covers drugs administered in a provider setting, and patients served under the program include those fighting diseases such as cancer, multiple sclerosis, macular degeneration, rheumatoid arthritis and primary immunodeficiency diseases – those most in need of the Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , ,

How Animal Biotech Harnesses Nature’s Power to Fight Disease


Forbes’ GMO Answers column looks at the tremendous potential of animal biotechnology to combat human disease.  Under the theme “One Health,” these technologies – and the roadblocks that are preventing them for commercialization – are the focus on this week’s Animal Biotech Summit in Bethesda, Md. Today’s column was authored by Eddie Sullivan, Ph.D., CEO and co-founder of SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company in Sioux Falls, S.D.  SAB’s technology (described below) Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: ,

Be Prepared This Flu Season and Get Vaccinated

Copyright sanofi pasteur

It can only mean one thing when long summer days have come to an end, school is back in session, and cooler temperatures are on the horizon with the arrival of fall – flu season is coming! As influenza activity begins to rise in October, be prepared and plan to protect yourself, your family, and those around you by getting your annual flu vaccine. The CDC advises that everyone six months and older get vaccinated Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Insurers Still Spreading Falsehoods To Protect Their Bottom Line


For the better part of a year, BIO has been on a mission to shine a light on the insurance industry and what they and their allies do to restrict patient access to innovative breakthroughs. Apparently, we’re not the only ones who’ve caught on to the falsehoods spread by insurers to protect their bottom line. Kaiser Health News’ Chad Terhune says Consumers Union has taken aim at two California Blue Cross Blue Shield insurers who Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

New Study Debunks Myths About Orphan Drug Act and Rare Disease Drug Costs


The Orphan Drug Act has been targeted recently by the insurance industry and its allies in the media, but in the face of withering criticism and unjustified allegations, a new study from IMS Health shows that concerns about rare drug costs are completely misguided. Kaiser Health News’ Sarah Jane Tribble reports the study, published in Health Affairs, “analyzed U.S. pharmaceutical spending from 2007 to 2013 on more than 300 drugs that had orphan approval under Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,